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shown to rescue almost all refractory autoimmune
diseases. The chimeric antiCD20 antibody is one of the
world’s most successfully therapeutic antibodies, with sales
of approximately US$5.6 billion in 2009.1 Rituximab was
first approved in 1997 by the US Food and Drug Adminis-
tration (FDA) for treatment of B cell malignancies, and is
now expanded to autoimmune indications, such as lupus
nephritis, multiple sclerosis and vasculitis, particularly
refractory autoimmune diseases that usually cause fatal
outcomes.2e8 Autoimmunity is a complex process that
involves the interaction of multiple immune cell types. B
cells are thought to play a central role in the autoimmune
disease serving as precursors to autoantibody-secreting
plasma cells. In addition to producing antibodies, B cells
are able to present antigen to T cells. Their depletion also
results in the removal of antigen-presenting cells, reduced
expression of molecules responsible for T cell costimulatory
signals, and reduced levels of immune complexes formed
between autoreactive antibodies and their antigen.
There are certain refractory autoimmune diseases
successfully treated by rituximab including antiphospholipid
syndrome (APS), thrombotic thrombocytopenic purpura
(TTP), antineutrophil cytoplasmic antibody (ANCA) vasculitis,
refractory rheumatoid arthritis, refractory juvenile derma-
tomyositis and refractory idiopathic thrombocytopenic* Corresponding author. Department of Pediatrics, Show Chwan
Memorial Hospital, Changhua, Taiwan.
E-mail address: yangkd.yeh@hotmail.com (K.D. Yang).
0929-6646/$ - see front matter Copyright ª 2012, Elsevier Taiwan LLC
doi:10.1016/j.jfma.2011.05.004purpura (ITP) (Table 1). In refractory APS, rituximab
(100e375 mg/m2) decreased anticardiolipin antibody levels
from 20.6 standardized IgG antiphospholipid units (GPLU)
to undetectable levels in six of seven patients 6 to 9 months
after treatment, and caused a high response ratedmore
than 90%din another report.2
In refractory TTP, which usually causes a fatal
outcome, rituximab achieved 92% complete response rate
associated with the disappearance of ADAMTS-13 inhibi-
tors and no subsequent relapses in a median follow-up of
24 months (range, 13e84 months).3 In refractory ANCA
vasculitis, a retrospective study showed that complete
remission occurred in 49 of the 65 patients (75%), partial
remission in 15 (23%), and no response only in one (2%) in
UK.4 In refractory rheumatoid arthritis (RA), rituximab
was approved by the FDA and European Medicine Agency
for the treatment of RA after antiTNFa treatment failure.5
In refractory juvenile dermatomyositis, a case report
showed that three of four patients showed clinical
improvement.6 In refractory ITP, only two of the 18
patients treated with rituximab were classified as thera-
peutic failures (11%).7 In patients with refractory Sjo¨g-
ren’s syndrome, the first double-blind study of rituximab
showed a favorable result from a randomized trial to
receive either two infusions of rituximab or placebo along
with steroids.8
These promising results have shared a light to treat all
autoimmune diseases by the antiCD20 strategy, particularly
the most prevalent autoantibody disease, systemic lupus
erythematosus (SLE). Unfortunately, the antiCD20& Formosan Medical Association. All rights reserved.
Table 1 Favorable and unfavorable benefits and side effects of rituximab treatment for autoimmune diseases.
Results Autoimmune diseases Response rates
Favorable
results
Refractory APS2 90% Remission
Refractory TTP3 92% Complete response
Refractory ANCA vasculitis4 1% No response
Refractory rheumatoid arthritis after failure of etanercept treatment5 RTXþMTX vs. placeboþMTX: ACR20 (51% vs. 18%)
Refractory juvenile dermatomyositis6 75% (3 out of 4 cases)
Refractory Sjo¨gren’s syndrome7 Significant improvement in fatigue visual analog
scale in the rituximab group (p< 0.001)
Refractory ITP8 11% therapeutic failure
Unfavorable
results
Add-on therapy for SLE with conventional treatment2 No better than conventional therapy
Macrophage Activation Syndrome Refractory lupus-associated macrophage activation
syndrome (two cases)
Worsening psoriasis after Rituximab9 Two case reports
Side effects Common side effects: Infections, infusion hypersensitivity,
hypogammaglobulinemia
Rare side effects: reactivation of hepatitis B virus infection,
tumor lysis syndrome, progressive multifocal leukoencephalopathy
182 L.-Y. Lin et al.treatment added on the conventional treatment did not
show a significant benefit over conventional treatments.2
Moreover, not all refractory autoimmune diseases respon-
ded to the antiCD20 therapy. Some case reports showed
that rituximab failed to rescue autoimmune associated
macrophage activation syndrome (MAS), and caused
a worsening psoriasis.9 In fact, psoriasis and MAS are known
to be mediated by cell-mediated diseases, and patients
with psoriasis responded to anticell immunity monoclonal
antibody (Ustekinumab: antiIL12/23 monoclonal antibody).
The antiB cell strategies may be suitable for autoantibody-
mediated diseases but not cell-mediated diseases. Another
strategy is to specifically target the receptors of auto-
antigen (self-deoxynucleic acid, self-DNA), such as TLR7
and TLR9 which could initiate autoantibodies directed
against self-DNA. Evidence has recently shown that
abnormal recognition of TLR7 and TLR9 was involved in the
pathogenesis of SLE, and inhibitors of TLR7 and TLR9 could
improve lupus manifestations. Antagonists of TLR7 and/or
TLR9 share the highlight for better specific target therapy
of SLE and other autoimmune diseases.10
There are some other antiB cell monoclonal antibodies
which have been developed, such as antiCD19 (Blinatumo-
mab), antiCD22 (Epratuzumab), and antiCD52 (Alemtuzu-
mab). The results of several large clinical trials using antiB
cell surface markers to nonrenal or renal lupus patients
has surprisingly not been successful.2 Recently, another
type of monoclonal antibody directed against soluble B cell
activation molecule, called antiBLyS/BAFF (Belimumab),
which targets mature B cells but not precursor B cells, has
shown promising clincial trials for SLE patients.2
Depletion of B cells by rituximab (chimeric monoclonal
antibodies) causes a minimal-to-moderate decrease in total
immunoglobulin levels during a few courses of treatment.
Most of the common side effects of rituximab on the patients
with autoimmune disease are minimal and tolerable,
including drug-infusion reaction, infections and other rare
sideeffects, suchas reactivationof hepatitis B virus infection
in patients with nonHodgkin lymphoma (NHL), tumor lysis
syndrome in lymphoma patients, and rituximab-induced
mucocutaneous reactions and progressive multifocal leu-
koencephalopathy. The next generation of antiB cellantibodies will be fully humanized monoclonal antibodies,
whichmay induce less side effects and be suitable formaking
formulations for subcutaneous use instead of intravenous
use. These trends will benefit autoimmune patients and
increase the convenience of medication in the future.
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